abstract: UNASSIGNED: e18545 Background: Traditionally, the standard of care for aggressive @entity1893 has been @entity5948 based bolus @entity7730 ( @entity7730 ), with or without rituximab and consolidation radiotherapy to bulky disease. Up to 40 % of @entity1 will relapse with this approach. The NCI designed regimen, DA EPOCH-R, is a rationally designed approach based on dose and schedule optimization which has been reported to overcome adverse effects such as @entity5 proliferation. METHODS: We retrospectively reviewed all @entity1 with aggressive @entity1893 receiving dose adjusted EPOCH+/-R in our institution. @entity1 demographics, pathology, stage, International Prognostic Index (IPI), dose intensity, @entity137 , response and outcomes were assessed. RESULTS: Forty three @entity1 were treated with DA EPOCH+/-R in a four year period. Of those, 17 (40%) were female. The median age was 51 years, range 20-87 years. The majority (84 %) of @entity1 had @entity1892 ( @entity1892 ). Only 2 @entity1 received this regimen in the relapsed setting. @entity1 had stage IIB or higher disease in 70%, in fact 53% had stage IV disease. Sixteen @entity1 (38%) had an IPI of three or more. A median of 6 cycles (range 1-6) have been administered. In total, 207 cycles were administered; dose intensity was maintained in 75%. Forty one @entity1 were evaluable for response. 78% of @entity1 achieved CR and 5% PR. Of those with a low IPI score (<= 2), 84% responded. In the high IPI group (>2), 87% responded. 51% of cycles resulted in grade 4 @entity1398 and 10% grade 4 @entity882 . Grade 3 non-hematological @entity137 was seen in 11% of cycles; only one cycle resulted in grade 4 @entity137 . CONCLUSIONS: We await the results of the CALGB phase III randomized study comparing R- @entity7730 to DA R-EPOCH in aggressive B-cell @entity1893 with interest. Our review demonstrates reproducible outcomes and acceptable @entity137 similar to the NCI published experience.

title: Dose-adjusted infusional @entity7730 with/without rituximab (DA EPOCH+/-R) in aggressive @entity1893 ( XXXX ): A single-institution experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B cell NHL']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity7730 :: ('MESH:D064146', 'Disease') :: ['CHOP', 'chemotherapy']

answer: @entity1893 :: (MESH:D008228,Disease) :: ['NHL']


abstract: OBJECTIVE: Many @entity1 with major @entity308 ( @entity4696 ) or @entity162 ( @entity162 ) experience impairments in daily life. We investigated whether @entity1 with @entity4696 ( @entity4696 -s), recurrent @entity4696 ( @entity4696 ), and @entity162 differ in functional impairments, whether time since last episode (syndromal state, in 4 categories) contributes to impairment, whether this association is moderated by diagnosis, and the role of @entity308 . METHOD: Data were derived from 1,664 @entity1 in the Netherlands Study of @entity308 and @entity148 ( @entity4696 -s, n = 483; @entity4696 , n = 1,063; @entity162 , n = 118), from 2006 into 2009. In additional analyses, 530 healthy controls were included. DSM-IV-TR diagnosis and information about syndromal state were based on the Composite International Diagnostic Interview. Psychosocial impairment was assessed with the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Adjusted associations between diagnosis, @entity73 , and @entity308 severity were investigated. RESULTS: Syndromal state not being taken into account, @entity1 with @entity162 experienced more functional impairment than @entity1 with @entity4696 -s or with @entity4696 , and in all diagnostic groups, impairments decreased with increasing time since last episode. However, impact of syndromal state on functioning showed a different course between diagnostic groups (mean [SD] WHODAS score: current: @entity4696 -s 30.8 [2.8], @entity4696 32.7 [0.9], @entity162 37.7 [2.1], P = .07; recently remitted: @entity4696 -s 21.7 [3.5], @entity4696 24.0 [1.2], @entity162 22.1[3.2], P = .7; remitted: @entity4696 -s 10.6 [3.7], @entity4696 21.6 [1.4], @entity162 19.2 [4.4], P = .02; remitted > 1 year: @entity4696 -s 13.3 [0.6], @entity4696 14.7 [0.5], @entity162 17.1 [2.2], P = .8). @entity308 severity accounted for these differences. Moreover, functioning in all remitted @entity1 remained impaired when compared to that in healthy controls. CONCLUSION: Functional recovery may take up to 1 year after syndromal remission in recurrent @entity308 , mainly due to residual @entity308 , emphasizing the need for prolonged continuation treatment.

title: Functional versus syndromal recovery in @entity1 with major XXXX and @entity162 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'BD']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressive disorder', 'depressive symptoms', 'depression', 'depressive and bipolar disorder']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['syndromal state, impairment']

entities_list: @entity4696 :: ('MESH:D003865', 'Disease') :: ['MDD-r', 'single-episode MDD', 'MDD']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depressive disorder']


abstract: PURPOSE: G protein-coupled receptors (GPCRs) are a superfamily of membrane proteins of vast pharmaceutical interest. Here, we describe a graph theory-based analysis of the structure of the @entity2162 ( @entity2162 ), a prototypical @entity31679 . In particular, we illustrate the network of direct and indirect interactions that link each @entity535 residue to any other residue of the receptor. METHODS: Networks of interconnected @entity535 residues in proteins are analogous to social networks of interconnected @entity1 . Hence, they can be studied through the same analysis tools typically employed to analyze social networks - or networks in general - to reveal patterns of connectivity, influential members, and dynamicity. We focused on the analysis of closeness-centrality, which is a measure of the overall connectivity distance of the member of a network to all other members. RESULTS: The residues endowed with the highest closeness-centrality are located in the middle of the seven transmembrane domains (TMs). In particular, they are mostly located in the middle of TM2, @entity16544 , TM6 or TM7, while fewer of them are located in the middle of @entity26381 , TM4 or @entity16544 . At the cytosolic end of TM6, the centrality detected for the active structure is markedly lower than that detected for the corresponding residues in the inactive structures. Moreover, several residues acquire centrality when the structures are analyzed in the presence of ligands. Strikingly, there is little overlap between the residues that acquire centrality in the presence of the ligand in the blocker-bound structures and the agonist-bound structures. CONCLUSIONS: Our results reflect the fact that the receptor resembles a bow tie, with a rather tight knot of closely interconnected residues and two ends that fan out in two opposite directions: one toward the extracellular space, which hosts the ligand binding cavity, and one toward the cytosol, which hosts the G protein binding cavity. Moreover, they underscore how interaction network is by the conformational rearrangements concomitant with the activation of the receptor and by the presence of agonists or blockers.

title: Graph analysis of @entity2162 structures: a "social network" of XXXX residues.

entities_list: @entity2162 :: ('154', 'Gene') :: ['b2 adrenergic receptor', 'b2 AR']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

answer: @entity31679 :: (441931,Gene) :: ['GPCR']


abstract: It has been shown previously that recombinant virus-like particles (VLPs) of papillomavirus can induce VLP-specific humoral and cellular immune responses following parenteral administration. To test whether mucosal administration of @entity10368 ( @entity10368 ) VLPs could produce mucosal as well as systemic immune responses to VLPs, 50 micrograms chimeric @entity10368 VLPs containing an @entity1799 E7 CTL epitope (BPVL1/E7 VLP) was administered intranasally to @entity19 . After two immunisations, L1-specific serum IgG and IgA were observed. L1-specific IgG and IgA were also found in respiratory and vaginal secretions. Both serum and mucosal antibody inhibited papillomavirus VLP-induced agglutination of RBC, indicating that the antibody induced by mucosal immunisation may recognize conformational determinants associated with @entity778 . For comparison, VLPs were given intramuscularly, and systemic and mucosal immune responses were generally comparable following systemic or mucosal delivery. However, intranasal administration of VLP induced significantly higher local IgA response in lung, suggesting that mucosally delivered HPV VLP may be more effective for mediating local mucosal immune responses. Intranasal immunisation with HPV6b L1 VLP produced VLP-specific T proliferative responses in splenocytes, and immunisation with BPVL1 VLP containing an @entity1799 E7 CTL epitope induced E7-specific CTL responses. We conclude that immunisation with papillomavirus VLPs via mucosal and intramuscular routes, without adjuvant, can elicit specific antibody at mucosal surfaces and also systemic VLP epitope specific T cell responses. These findings suggest that mucosally delivered VLPs may offer an alternative HPV VLP vaccine strategy for inducing protective humoral @entity1200 , together with cell-mediated immune responses to eliminate any cells which become infected.

title: Mucosal immunisation with papillomavirus virus-like particles elicits XXXX in @entity19 .

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['virus neutralisation']

entities_list: @entity10368 :: ('10561', 'Species') :: ['BPV1', 'bovine papillomavirus type 1']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['immunity to anogenital HPV infection']

answer: @entity1200 :: (MESH:D007154,Disease) :: ['systemic and mucosal immunity']


abstract: BACKGROUND AND AIMS: The purpose of this study was to investigate the potential therapeutic efficiency of @entity4025 in the treatment of experimental @entity46 in @entity35 . SETTINGS AND DESIGN: Experimental study was carried out in a University hospital. MATERIALS AND METHODS: Endometriosis was surgically induced in 24 female @entity35 . Four weeks after this procedure, the viability and dimensions of the @entity46 foci were recorded. @entity35 were then randomly divided into three groups: (1) Control group (n = 8); (2) low dose (10 mg/kg) @entity4025 group (n = 8); (3) high dose (100 mg/kg) @entity4025 group (n = 8). At the end of the 7-day treatment, blood samples were taken and laparotomy was performed. The endometrial implants were processed for biochemical, histological and immunohistochemical studies. STATISTICAL ANALYSIS USED: The Kruskal-Wallis H test and one-way ANOVA test were used. RESULTS: @entity4025 -treated @entity35 showed significantly reduced endometriotic implant volumes (P = 0.004). After treatment, a significant and dose-dependent increase in activities of @entity224 dismutase and @entity2041 peroxidase in serum and tissue of the @entity35 in Group 2 and Group 3 was detected. Similarly, serum and tissue @entity1234 levels and tissue catalase levels were significantly higher in Group 3 than that of control animals. Histological scores and proliferating cell nuclear antigen expression levels were also significantly reduced in Group 2 and Group 3 than that of control group. CONCLUSION: In a @entity35 @entity46 model, @entity4025 showed potential ameliorative effects on endometriotic implants probably due to its potent antioxidative properties.

title: XXXX successfully treats experimental @entity46 through modulation of oxidative stress and lipid peroxidation.

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malonyl dialdehyde']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity4025 :: ('MESH:C059514', 'Chemical') :: ['resveratrol', 'Resveratrol']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity4025 :: (MESH:C059514,Chemical) :: ['Resveratrol']


abstract: OBJECTIVE: To report on adverse reactions to intravenous nonionic @entity1496 contrast media and evaluate the usefulness of monitoring vital signs. MATERIAL AND METHODS: A prospective study of 1537 consecutive @entity1 who received contrast-enhanced CT with nonionic @entity1496 was performed. @entity551 , pulse rate and arterial blood @entity26 saturation were monitored. Severity of adverse reactions was classified as minor, intermediate and severe. RESULTS: A total of 64 adverse reactions developed in 57 @entity1 . The overall prevalence was 3.7% (57/1537). The most common symptom was @entity390 (18/64) followed by pharyngeal discomfort (11/64). One @entity1 had a severe reaction consisting of prolonged @entity551 . Four @entity1 had an intermediate reaction, three transient @entity551 or @entity101 and one extensive @entity110 and @entity4 . In two out of four @entity1 who became @entity551 or @entity101 , the reactions developed without any obvious clinical symptoms. CONCLUSIONS: Severe or life-threatening acute adverse reactions to intravenous nonionic @entity1496 contrast media may develop without any obvious clinical symptoms. Monitoring vital signs is very helpful for early detection.

title: Adverse reactions to nonionic XXXX in contrast-enhanced computed tomography: usefulness of monitoring vital signs.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['facial edema']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive', 'Systolic and diastolic arterial blood pressure', 'hypotension']

entities_list: @entity110 :: ('MESH:D014581', 'Disease') :: ['urticaria']

answer: @entity1496 :: (MESH:D007455,Chemical) :: ['iodine']


abstract: Neurotrophins such as nerve growth factor (NGF) and @entity9140 ( @entity9140 ) are potent mediators of neuronal plasticity in the adult. There is increasing evidence that they regulate a variety of immune functions as well. Thus, neurotrophins are candidate molecules for neuroimmune interactions in @entity56 @entity565 , where elevated neurotrophin levels have been reported. In a @entity19 model of @entity56 airway @entity32 we have identified macrophages and lymphocytes as additional cellular sources of NGF and @entity9140 in the inflamed lung. There was an unusual time course of @entity9140 in bronchoalveolar lavage fluid. @entity9140 levels peaked 1 week after the last allergen challenge, and did not correlate with the time course of the inflammatory response. In a series of experiments using blocking anti-NGF and anti- @entity9140 antibodies, we have shown that NGF specifically enhances @entity32 and the @entity56 early-phase response. In contrast, @entity9140 influenced chronic @entity1224 without affecting @entity32 . Using @entity19 overexpressing NGF in the airway epithelium, we have confirmed the data obtained from anti-NGF experiments. Allergen-challenged NGF overexpressors displayed a markedly @entity32 , early-phase response, and sensory irritation compared to wild-type @entity19 . Studies with @entity20384 (-/-) knockout @entity19 showed that these NGF effects are at least in part mediated by the low-affinity neurotrophin receptor. Thus, our experiments suggest that NGF and @entity9140 have a profound, but differential impact on @entity56 airway dysfunction.

title: Neurotrophins in XXXX airway dysfunction: what the @entity19 model is teaching us.

entities_list: @entity9140 :: ('12064(Tax:10090)', 'Gene') :: ['brain-derived neurotrophic factor', 'BDNF']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'augmented airway inflammation']

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'transgenic mice']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['bronchial asthma']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway obstruction and local neuronal hyperreactivity']

answer: @entity56 :: (MESH:D004342,Disease) :: ['allergic']


abstract: BACKGROUND: Two studies were conducted to test claims that pragmatic @entity73 (PLI - previously referred to as @entity10791 ) is simply another term for @entity2438 or @entity245 not otherwise specified (PDDNOS). METHOD: In Study 1, 21 @entity1 aged from 6 to 9 years with @entity73 were subdivided on the basis of the @entity1 's Communication Checklist into 13 cases of pragmatic @entity73 (PLI) and eight cases of typical @entity10870 ( @entity10870 ). Parents completed the @entity23546 ) and the Social Communication Questionnaire (SCQ), and the @entity1 were given the Autism Diagnostic Observation Schedule - Generic (ADOS-G). In Study 2, a further 11 @entity1 with @entity10870 and 18 with PLI were assessed using the SCQ and ADOS-G. In addition, six @entity1 diagnosed with high-functioning @entity2438 and 18 normally developing @entity1 were assessed. RESULTS: There was good agreement between ADI-R and SCQ diagnoses, but poor agreement between diagnoses based on these parental report measures and those based on ADOS-G. In many @entity1 , symptom profiles changed with age. Four PLI @entity1 from Study 1 and one from Study 2 met criteria for @entity2438 on both parental report (ADI-R or SCQ) and ADOS-G. Many of the others showed some autistic features, but there was a subset of @entity1 with pragmatic difficulties who were not diagnosed as having @entity2438 or PDDNOS by either instrument. These @entity1 tended to use stereotyped language with abnormal intonation/prosody, but they appeared sociable and communicative, had normal nonverbal communication, and showed few abnormalities outside the language/social communication domains. CONCLUSIONS: Presence of pragmatic difficulties in a @entity1 with communication problems should prompt the clinician to evaluate autistic symptomatology, but it is dangerous to assume that all @entity1 with pragmatic difficulties have @entity2438 or PDDNOS.

title: Exploring the borderlands of @entity2438 and XXXX : a study using standardised diagnostic instruments.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'child']

entities_list: @entity23546 :: ('64222', 'Gene') :: ['Autism Diagnostic Interview - Revised (ADI-R']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['language impairments', 'language impairment']

entities_list: @entity2438 :: ('MESH:D001321', 'Disease') :: ['autistic disorder', 'autism']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['pervasive developmental disorder']

entities_list: @entity10870 :: ('OMIM:606712', 'Disease') :: ['specific language impairment', 'SLI-T']

entities_list: @entity10791 :: ('MESH:D007805', 'Disease') :: ['semantic-pragmatic disorder']

answer: @entity10870 :: (OMIM:606712,Disease) :: ['specific language impairment']


abstract: An observational cross-sectional study of 50 cases of chronic @entity16581 @entity1 was conducted in Bangabandhu Sheikh Mujib Medical University (BSMMU) and some other tertiary level hospitals of Dhaka city from August 2008 to July 2010. @entity1 required laparotomy for different modalities of surgical treatment to manage chronic @entity16581 were included in the study. Biopsy was taken from panceatic duct containing stone during laparotomy to determine the histopathological changes. Among 50 cases female predominance was observed. Male, female ratio was 2:3. Majority (62%) @entity1 were in 20 to 40 years age group. Female presented earlier than male (20-30 years and 30-40 years respectively). All @entity1 complained recurrent attack of @entity158 . Other presentations were @entity6 (74%), @entity3147 and @entity353 (56%), steatorrhoea (24%) and @entity1087 (12%). @entity420 was found in 3(6%) @entity1 (2 male and 1 female) and rests were @entity1689 . Several studies showed the association between chronic @entity16581 and @entity788 . Further large scale study is required to find out the national incidence level.

title: XXXX and @entity788 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity1689 :: ('MESH:D050500', 'Disease') :: ['chronic pancreatitis']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['epigastric pain']

entities_list: @entity16581 :: ('MESH:C566837', 'Disease') :: ['calcific pancreatitis']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['Adenocarcinoma']

answer: @entity16581 :: (MESH:C566837,Disease) :: ['Chronic calcific pancreatitis']


abstract: Inhibitors of the @entity1426 cascade were given to pregnant @entity35 during the critical period for morphogenesis of the external genitalia. Groups treated subcutaneously (s.c.) with 0.1 or 0.25 mg/kg/day of @entity2995 (TA) on gestational days (GD) 14-19 had male fetuses on GD 20 with moderate @entity393 (AGD), but gross and histological examinations revealed no alterations to the genital tubercle (i.e., no @entity2650 ). The s.c. coadministration of @entity1426 at 100 mg/kg/day had minimal to no effect on AGD in the TA-exposed groups. No effect on AGD was observed in male fetuses from groups administered @entity117 orally at 150 mg/kg/day, and only a 6% decrease was observed in the 300-mg/kg/day group. Neither TA nor @entity117 adversely affected AGD of female fetuses. In another study, TA was administered on GD 11-19 at dose levels of 0.05 and 0.1 mg/kg/day, and dams were allowed to deliver. High-dose male offspring examined on @entity227 ( @entity227 ) 23, had moderate decreases in AGD. In both studies with TA, there were also significant decreases in offspring weights. The contribution of the decreased weight to the decrease in absolute AGD was examined by a variety of methods (ratio of AGD to cube root of weight or biparietal distance, comparison to weight-matched controls, and covariance analysis). We conclude that TA caused a specific decrease in AGD on GD 20 that was largely reversed by @entity227 23. When examined as adults (8 weeks old), the external genitalia of TA-exposed offspring were normal. Thus, the TA-induced decreases in AGD on GD 20 did not predict irreversible @entity600 . TA also caused other effects, which included a somewhat flattened genital tubercle and apparently thinned and glossy skin between the tubercle and the anus in both sexes on GD 20 and @entity227 23, but not as adults. In addition, there were high pup mortality and high incidences of @entity4239 and omphalocele (in the 0.25-mg/kg/day group only). @entity117 at 75 or 150 mg/kg/day and a specific lipoxygenase inhibitor (L-656,224) at 1,000 or 2,000 mg/kg/day were also administered from GD 14 to 19, and no offspring effects were observed. Thus, of the three agents that potentially inhibit the @entity1426 cascade, only @entity2713 produced moderate effects on @entity35 external genitalia that were largely reversible.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Reversible effects of @entity2713 and lack of effects with XXXX or L-656,224 on external genitalia of male @entity35 exposed in utero.

entities_list: @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['postcoitum day', 'PCD']

entities_list: @entity2650 :: ('MESH:D007021', 'Disease') :: ['hypospadias']

entities_list: @entity4239 :: ('MESH:D008844', 'Disease') :: ['micrognathia']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformation']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['decreases in absolute anogenital distance']

entities_list: @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']

answer: @entity117 :: (MESH:D001241,Chemical) :: ['aspirin']


abstract: OBJECTIVE: This study investigated the prospective relationships between @entity146 ( @entity308 and @entity148 ) and body mass index (BMI) in @entity1 with and without excessive @entity1017 during pregnancy. The secondary aim was to examine whether @entity146 and BMI were predictive of one another. Two models were tested: the first depicted @entity308 predicting BMI, and the second model depicted BMI predicting @entity308 . DESIGN AND @entity1 : @entity1 completed questionnaires at three time points throughout pregnancy, which comprised of the @entity308 , @entity148 and Stress Scale-21 and self-reported weight. Height and weight were also reported retrospectively at T1 to calculate pre-pregancy BMI category. To calculate total gestational @entity1017 (GWG), pre-pregnancy weight was substracted from weight at 36 weeks gestation. METHODS: 183 @entity1 were tracked during pregnancy; Time (T)1 (mean=16.50 weeks of gestation, SD=.92), T2 (mean=24.40 weeks of gestation, SD=.92), and T3 (mean=32.61 weeks gestation, SD=.88). The sample was divided into those for whom @entity1017 exceeded the guidelines for GWG (excessive gestational @entity1017 ; EGWG), and those who for whom it did not. Multigroup path analyses compared the longitudinal relationships between @entity308 and BMI during pregnancy for @entity1 with and without EGWG. FINDINGS: BMI did not predict @entity308 . @entity308 at T1, did however predict higher BMI at T2 for @entity1 without EGWG. @entity148 symptoms and BMI were not related, regardless of GWG status. CONCLUSION: These findings suggest that @entity308 may precede increased BMI during pregnancy in @entity1 who do not gain weight excessively. There may be longitudinal relationships between @entity308 and BMI during pregnancy; however, further research is required to identify the mechanisms that link these health outcomes and inform the focus of intervention design.

title: Relationships between @entity146 and body mass index in XXXX with and without excessive @entity1017 during pregnancy.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Women', 'PARTICIPANTS']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressive symptoms', 'depressive', 'Depressive symptoms', 'depressive or anxiety symptoms']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental health symptoms']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety symptoms', 'Anxiety']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: Insensitive acetylcholinesterase (AChE) has been shown to be responsible for resistance to @entity2958 and @entity9159 in a number of arthropod species. Some arthropod genomes contain a single Ace gene, while others including mosquitoes contain two genes, but only one confers insecticide resistance. Here we report the isolation of the full-length cDNA and characterization of the complete genomic DNA sequence for the Ace1 gene in the @entity4224 , @entity4224 . The Ace1 homolog in other mosquito species has been associated with insecticide resistance. The full-length cDNA consists of 2721bp and contains a 2109bp open reading frame that encodes a 702 @entity535 protein. The @entity535 sequence is highly conserved with that of other mosquitoes, including greater than 90% identity with Culex spp. and about 80% identity with @entity313 . The genomic DNA sequence includes 138,970bp and consists of eight exons with seven introns ranging from 59 to 114,350bp. Exons 2 and 8 show reduced @entity535 conservation across mosquito species, while exons 3-7 are highly conserved. The Ace1 introns in Ae. aegypti reflect a high frequency of repetitive sequences that comprise about 45% of the total intron sequence. The Ace1 locus maps to the p-arm of chromosome 3, which corresponds to the orthologous genome regions in Culex spp. and An. gambiae.

title: Molecular cloning and characterization of the complete acetylcholinesterase gene (Ace1) from the mosquito XXXX with implications for comparative genome analysis.

entities_list: @entity4224 :: ('7159', 'Species') :: ['yellow fever mosquito', 'Aedes aegypti']

entities_list: @entity2958 :: ('MESH:D010755', 'Chemical') :: ['organophosphates']

entities_list: @entity9159 :: ('MESH:D002219', 'Chemical') :: ['carbamates']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity313 :: ('7165', 'Species') :: ['Anopheles gambiae']

answer: @entity4224 :: (7159,Species) :: ['Aedes aegypti']


abstract: OBJECTIVE: Mutations in the @entity2539 gene result in @entity13601 . The classic clinical presentation is primary @entity1887 in early life and @entity6126 at the time of expected puberty, but recent data have expanded the phenotypic spectrum of @entity2539 mutations. We report the occurrence of an @entity4545 -secreting @entity652 in a @entity1 with @entity13601 . DESIGN AND METHODS: Detailed clinical, radiological and pathological investigation of the @entity977 . Genomic analysis of the @entity2539 gene in the @entity1 and his mother. RESULTS: In this @entity1 , primary @entity177 had been diagnosed at 3 years of age and, despite replacement therapy, at 30 years of age progressive pigmentation developed and @entity227 followed. @entity4545 was 24 980 pg/ml and nuclear magnetic resonance disclosed a huge @entity977 . Three transsphenoidal operations and radiotherapy were necessary to remove the @entity5 mass and control @entity4545 secretion. Histologically, the @entity652 was composed of chromophobic and basophilic neoplastic cells with positive immunostaining for @entity4545 . Moreover, a novel mutation was found both in the @entity1 and his mother: a 4 bp insertion (AGCG) at nucleotide 259, in exon 1 resulting in a frame shift and premature termination. CONCLUSIONS: This case suggests that in @entity509 congenita the development of a @entity977 should be considered when a sudden rise of @entity4545 occurs despite adequate @entity134 substitution.

title: Corticotroph @entity977 in a XXXX with @entity13601 due to a novel mutation of the @entity2539 gene.

entities_list: @entity13601 :: ('MESH:C536757', 'Disease') :: ['X-linked congenital adrenal hypoplasia']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['impairment of the visual field']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['adrenal failure']

entities_list: @entity509 :: ('MESH:C538429', 'Disease') :: ['adrenal hypoplasia']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenoma']

entities_list: @entity6126 :: ('MESH:D007006', 'Disease') :: ['hypogonadotropic hypogonadism']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: INTRODUCTION: As yet there is no single reliable and accurate method for detection of neck lymph node @entity3 . Therapeutic approaches differ from one author to other. The aim of this paper was to establish the extent to which, with good control of primary process, we can control spreading of @entity5 by means of selective neck dissection. MATERIAL AND METHOD: This retrospective study included 595 surgically treated @entity1 in the period 1990-1998. There were 525 @entity1 with @entity5 , and 70 @entity1 with @entity5 . Preoperative diagnostics of enlarged lymph nodes was based on palpation of the neck, without CT, US, NMR diagnostics. With all risky N0 @entity1 , selective neck dissection was performed for presence of occult @entity3 . Intraoperative frozen section analysis was not performed. Adjuvant radiatitherapy was performed in all @entity1 in whom presence of neck lymph node @entity3 was histologically proved. RESULTS: Selective lateral neck dissection was performed in 389 (65.4%) @entity1 . In 78 (20%) @entity1 , lymph node @entity3 were pathohistologically detected. In 5 (6.4%) transitional cellular @entity5 was histologically diagnosed, and the remaining 73 (93.6%) presented with @entity1544 . Postoperative radiation therapy was applied in 54 @entity1 (69.2%) while 24 (30.8%) were not irradiated. 5-year survival was achieved in 18 (23.1%), and 3-year survival was achieved in 15 (19.2%) @entity1 . Out of 45 @entity1 who lived less than tree year, 18 (40%) presented with metastatic relapse and fatal outcome. Relapse of neck @entity3 appeared in 12 (11.9%) on the side and in the zones of lymph nodes which were included in neck dissection. Recurrence of neck @entity3 appeared in 8.3% of @entity1 who were not irradiated postoperatively and in 32.1% of cases irradiated postoperatively. DISCUSSION: This study includes comparison of our results with results of literature data. CONCLUSION: Neck lymph node @entity3 point to advanced malignant process of the third or forth stage of the disease when results are the worst and 5-year survival decreases with or without adjuvant radiotherapy.

title: [Selective neck dissection in the treatment of pN1/2 lymph node XXXX in the neck].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant hypopharyngeal tumors', 'malignant disease', 'cancer', 'malignant laryngeal tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['squamous cell cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: OBJECTIVE: To determine the efficacy of adenovirus mediated suicide gene transduction combined with prodrug @entity4895 ( @entity10498 ) as a therapeutic protocol for @entity788 . METHODS: @entity5538 Deaminase( @entity1050 ) gene was cloned into pAdTrack- @entity2834 - @entity1050 , pAdTrack- @entity2834 - @entity1050 and pAdEasy-1 were recombined in bacteria. The newly recombined adenovirus (Ad)- @entity1050 containing green fluorescent protein (GFP) were packaged and propagated in 293 cells and purified by @entity6928 gradient centrifugation. @entity1 @entity3123 cell line-Patu8988 was infected with this virus, then 5FC was added. XTT assay was used to estimate relative numbers of viable cells. In vivo model of @entity788 was established by injecting 1.0 x 10(7) Patu8988 cells subcutaneously in Balb/c @entity19 . When @entity5 were palpable, Ad- @entity1050 was injected into each @entity5 and 5FC was administered. RESULTS: Positive clones were selected using endonuclease to digest the recombinants and the concentration of viral liquids containing the @entity1050 gene was 2 x 10(11) pfu /ml. Significant cytotoxic activity as shown for 5FC in the @entity1050 gene transduced 8988 cell line, while little effect was found in the nontransduced @entity3123 cells. Antitumor effect was observed in Patu8988 xenograft @entity19 with in situ @entity1050 gene transduction. CONCLUSIONS: @entity1050 gene mediated by adenovirus has high infectivity and may be useful for gene therapy in @entity3123 . These data demonstrate the use of an enzyme prodrug strategy in experimental @entity788 .

title: Adenoviral mediated suicide gene transfer in the treatment of XXXX .

entities_list: @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity4895 :: ('MESH:D005437', 'Chemical') :: ['5-fluorocytosine']

entities_list: @entity6928 :: ('MESH:C028019', 'Chemical') :: ['cesium chloride']

entities_list: @entity5538 :: ('MESH:D003596', 'Chemical') :: ['Cytosine']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']


abstract: BACKGROUND: Gene therapy is a new, experimental method of treatment in @entity1 with @entity453 ( @entity453 ). AIM: To determine the safety and efficacy of gene encoding @entity7 ( @entity1655 ) administered directly into the myocardium as the single treatment or combined with coronary artery by-pass grafting (CABG). METHODS: @entity7 gene transfer was performed in 22 @entity1 (20 male, 2 female, ages from 48 to 73 years old). A 200 micro g of the plasmid encoding @entity1655 was injected into the ischaemic myocardium which could not be surgically revascularised in @entity1 undergoing CABG (n=14), and 400 micro g - in @entity1 without CABG (n=8). The value of ejection fraction (EF), myocardial perfusion, angiogram, ventriculography, and @entity12118 consumption as well as quality of life were evaluated pre- and postoperatively. RESULTS: The majority of @entity1 had no complications and no fatal outcome was observed. Two @entity1 developed @entity583 . Left ventricular function values improved and the majority of @entity1 were free from angina 6 months after surgery. @entity1 reported improved quality of life and a reduction in @entity12118 usage. A reduction in the @entity154 detected by SPECT was also observed. In some @entity1 angiography revealed improved collateral filling. CONCLUSIONS: Direct myocardial administration of genes encoding @entity1655 can be an effective method of treatment in @entity1 with chronic and advanced @entity453 either as a supplementary treatment or as a single therapy.

title: Gene therapy of XXXX with phvegf165--early outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['ischaemic defects']

entities_list: @entity12118 :: ('CHEBI:28787', 'Chemical') :: ['nitroglycerine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: BACKGROUND: The @entity901 / @entity1487 / @entity4181 (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced @entity14 . In Japan, @entity901 was approved in April 2005. METHODS: To evaluate the objective @entity5 responses and feasibility ( @entity137 ) of FOLFOX regimens (FOLFOX4 and modified FOLFOX6, mFOLFOX6) in a predominantly Japanese population with refractory or advanced @entity14 in Japan, 51 consecutive @entity1 with histologically confirmed metastatic @entity694 who were treated between April 2005 and March 2006 were enrolled in a retrospective study. FOLFOX4 was used for treatment in 39% (first-line, 45%) of these @entity1 , and mFOLFOX6 was used for treatment in 61% (first-line, 61%). @entity5 responses were assessed radiologically, and @entity137 were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 regarding @entity137 other than @entity1897 . RESULTS: The objective response rates (in those who underwent first- or second-line therapy) were 50.0% and 8.7%, respectively. The @entity5 control rate (partial response [PR] + stable disease [SD]) was 80.4%. There were no @entity137 -related @entity204 . @entity1398 grade 3 was experienced in 20% of @entity1 , and often caused delay in the subsequent treatment course. Mild to moderate cumulative @entity1897 affected 78% of @entity1 . The incidence of @entity56 reactions to @entity901 in our study was lower than that in reported in Western countries. CONCLUSION: Both FOLFOX regimens have good efficacy in refractory or advanced @entity14 in a Japanese population, with an acceptable overall @entity137 profile.

title: @entity901 / @entity1487 / @entity4181 (FOLFOX4 and modified FOLFOX6) in XXXX with refractory or advanced @entity14 : post-approval Japanese population experience.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral sensory neuropathy']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['Neutropenia']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon or rectum cancer']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Endoscopic therapy for @entity548 is highly effective. Nevertheless, @entity548 recurs in 10% to 25% of cases, irrespective of the method of treatment used. Whether a second-look endoscopy with retreatment after initial hemostasis is of clinical value is controversial. A meta-analysis was performed to assess whether systematic second-look endoscopy with retreatment reduces the risks of recurrent @entity548 , salvage surgery, and @entity204 in @entity1 with peptic @entity1066 . METHODS: A systematic review was performed of randomized controlled studies of the value of second-look endoscopy in @entity1 with peptic @entity1066 published between 1990 and 2000. Four studies were selected according to predefined criteria. Two investigators extracted the data independently. Pooled risk estimates and number need to treat were calculated for each procedure. Heterogeneity of effects was tested. RESULTS: The absolute risk reduction in clinical recurrent @entity548 was 6.2% (p < 0.01). Absolute risk reduction for surgery and mortality were, respectively, 1.7% and 1.0% (not significant). The second look with retreatment significantly reduced the risk of recurrent @entity548 compared with control @entity1 (OR 0.64; 95% CI [0.44, 0.95]; p < 0.01), with a number needed to treat of 16. There was no heterogeneity among studies. The risk of surgery as well as the risk of @entity204 were not significantly influenced by the second-look endoscopy with retreatment (number needed to treat, respectively, 58 and 97). CONCLUSIONS: Systematic second-look endoscopy with retreatment significantly reduces the risk of recurrent @entity548 in @entity1 with peptic @entity1066 compared with control @entity1 , but it does not substantially reduce the risk of salvage surgery or mortality.

title: Outcome of endoscopic treatment for peptic XXXX : Is a second look necessary? A meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['GI bleeding', 'bleeding']

answer: @entity1066 :: (MESH:D014456,Disease) :: ['ulcer bleeding']


abstract: BACKGROUND: @entity3243 , atypical @entity3243 , and parathyromatosis can be differentiated relatively easily from typical @entity3243 , but distinguishing them from each other is more difficult. METHODS: A retrospective study of 28 consecutive @entity1 with @entity3243 , 7 @entity1 with atypical @entity3243 , and 13 @entity1 with parathyromatosis who were treated at the University of California at San Francisco Medical Center between 1966 and 2005 was performed. @entity1 demographics and clinical characteristics, indication for surgery, intraoperative findings, histopathologic characteristics, disease recurrence or persistence, site of invasion/metastases, and survival were compared in the 3 groups. RESULTS: @entity3243 (19 of 28 @entity1 ) and @entity652 (4 of 7 @entity1 ) were significantly more common in @entity1 , whereas parathyromatosis was more common in @entity1 (10 of 13 @entity1 ) (P = .02). A palpable neck mass and hoarseness were almost exclusively present in @entity1 with @entity3243 . Prior to the first parathyroid surgery, @entity1 with @entity3243 were found to have higher blood @entity460 levels (>/=14 mg/dL in 16 of 26 @entity1 [62%]), whereas only 1 of 6 @entity1 with @entity652 (17%) and no @entity1 with parathyromatosis were found to have profound @entity2741 (P < .01). Intraoperatively, @entity1 with @entity3243 and @entity652 presented with single lesions, whereas @entity1 with parathyromatosis had @entity66 . Histopathologic findings were well defined in @entity3243 , but some findings overlapped in the 3 @entity5 studied. CONCLUSIONS: @entity1 with @entity3243 often differ from those with atypical @entity3243 or parathyromatosis at the time of presentation because @entity1 with @entity3243 have more profound @entity2741 as well as invasive @entity5 . However, at times it is difficult to distinguish between these conditions both clinically and by final histologic examination.

title: XXXX , atypical @entity3243 , or parathyromatosis?

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'Patient', 'men']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['multiple small lesions']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3243 :: ('MESH:D010282', 'Disease') :: ['parathyroid adenoma', 'Parathyroid carcinoma', 'parathyroid carcinoma', 'parathyroid adenomas']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['atypical adenoma']

answer: @entity3243 :: (MESH:D010282,Disease) :: ['Parathyroid carcinoma']


abstract: The group 2 allergens of @entity7130 (Der p) and @entity8786 (Der f) are the major source of allergens for @entity1 allergic to house dust mites (HDMs). Previous studies have reported the existence of several polymorphic residues of Der p 2 and Der f 2. In this study, recombinant group 2 allergens of Der p (rDer p 2) and Der f (rDer f 2) were produced in @entity526 from the major isoforms of each cDNA, in order to evaluate their usefulness for the detection and standardization of allergens, and for the immunotherapy of @entity1 allergic to HDMs in Korea. cDNAs of the major isoforms of Der p 2 and Der f 2 were prepared from HDMs found in -Korean houses. The IgE-binding activities of the prepared rDer p 2 and rDer f 2 were analyzed using a Western blot immunodetection system and ELISA in the pooled sera of 10 @entity1 allergic to HDM. Both rDer p 2 and rDer f 2 bound to IgE in the pooled sera, and their activities were comparable to that of Der p 2 in HDMs. The rDer p 2-specific IgE level was higher than the rDer f 2-specific IgE level in @entity1 ' sera. The specificity of the monoclonal antibodies raised against both isoforms was analyzed by ELISA and immunogenicities of the antibodies were evaluated. Two out of four clones of rDer p 2-specific mouse monoclonal antibodies (IgG) reacted with both rDer p 2 and rDer f 2, whereas the other two did not react with rDer f 2. rDer f 2-specific monoclonal antibody reacted with both rDer f 2 and rDer p 2. The cross-reactivity of rDer p 2 and rDer f 2-specific monoclonal antibodies with both recombinant allergens indicates that epitopes responding to these antibodies are present. rDer p 2 and rDer f 2 may be useful for the detection and standardization of group 2 allergens of HDM and for the diagnosis and immunotherapy of @entity1 allergic to HDM in Korea.

title: Immune reactivity of recombinant group 2 allergens of house dust mite, XXXX , and @entity8786 .

entities_list: @entity8786 :: ('6954', 'Species') :: ['Dermatophagoides farinae']

entities_list: @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides pteronyssinus']

answer: @entity7130 :: (6956,Species) :: ['Dermatophagoides pteronyssinus']


abstract: OBJECTIVES: The objective was to assess the relationship between @entity341 ( @entity341 ) admission rates for Medicare beneficiaries with @entity662 and outcomes, specifically 30-day rates of @entity583 ( @entity583 ) and mortality. METHODS: Using a 20% random sample of Medicare beneficiaries in 2009, 158,295 beneficiaries with a primary diagnosis of @entity662 at the conclusion of their @entity341 visits were selected to assess outcomes based on the decision to hospitalize or discharge home. The proportions of these @entity1 admitted to inpatient or observation status at 2,219 U.S. hospitals were calculated, adjusting for differences in @entity1 and hospital characteristics. Both bivariate analysis and multivariable logistic regression were used to estimate the effect of the adjusted admission rates (designed to be a measure of care intensity) on @entity1 outcomes. Other covariates in the multivariable model included @entity1 demographics, medical conditions, and hospital utilization in the 30 days prior to the @entity341 visits. Results from the bivariate and multivariable analyses were compared for consistency. RESULTS: The adjusted Medicare admission rate for @entity341 @entity1 with @entity662 averaged 63% for the middle quintile of the @entity1 sample and ranged from 38% to 81% in the lowest and highest quintiles. The multivariable model yielded estimates of 3.6 fewer cases of @entity583 (95% confidence interval [CI] = 1.5 to 5.1 cases) and 2.8 fewer @entity204 (95% CI = 0.6 to 4.1 @entity204 ) per 1,000 @entity662 @entity1 associated with an admission rate of 81% versus 38%. The estimates from the bivariate analysis were of similar magnitude. CONCLUSIONS: Considerable variation exists across U.S. hospitals in @entity341 admission rates for Medicare @entity1 with @entity662 . Hospitals that approach admissions more conservatively (i.e., higher admission rates) in this population have lower rates of @entity583 and mortality.

title: Variation in @entity662 @entity341 admission rates and XXXX and @entity204 within 30 days in the Medicare population.

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: BACKGROUND: @entity67 has been shown to be an independent factor of @entity65 in @entity1 with @entity101 . Very often, @entity27 ( @entity27 ) and @entity209 ( @entity209 ) coexist with @entity101 ( @entity101 ) and may lead to @entity67 . Thus, the purpose of this study was to investigate whether @entity27 and @entity209 are associated with @entity67 in @entity1 with @entity101 independently from other factors, including age, left ventricular mass index (LVMI), and blood pressure (BP). METHODS: Data from 155 @entity1 (n = 92 @entity1 and 63 @entity1 ) were analyzed. All @entity1 underwent thorough examination, including biochemical evaluations, ambulatory blood pressure monitoring, polysomnography with assessment of @entity27 ( @entity27 ), and echocardiography. LVMI and diastolic function parameters were obtained. RESULTS: @entity1 were divided into 2 groups based on the presence or absence of @entity67 : group 1 (E' < 10cm/second; n=87) and group 2 (E' > 10cm/second; n = 68). @entity27 , LVMI, and 24-hour systolic BP/diastolic BP values were higher in group 1. E' correlated with @entity27 (r = -0.25; P < 0.001), LVMI (r = -0.36; P < 0.0001), 24-h systolic BP/24-h diastolic BP (r = -0.28, P < 0.001; r = -0.30, P < 0.001, respectively), @entity413 level (r = -0.26; P < 0.01), and @entity1144 (r = -0.28; P < 0.0001). In multivariable models decreased E' was independently related to the presence of @entity209 or @entity1144 when separate components of @entity209 were included in the model. Age and 24-hour systolic BP were independently associated with decreased E'. However, the relationship of decreased E' with 24-hour systolic BP was nonsignificant if LVMI was included in the multivariable model. CONCLUSIONS: @entity209 and @entity1144 were independently associated with @entity67 in @entity1 with @entity101 . @entity27 was not confirmed to be an independent factor of @entity67 .

title: Factors Associated With @entity67 in @entity1 With Resistant XXXX : Resist-POL Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'RHTN', 'resistant hypertension']

entities_list: @entity27 :: ('MESH:D020181', 'Disease') :: ['apnea/hypopnea index', 'obstructive sleep apnea', 'OSA', 'AHI']

entities_list: @entity1144 :: ('MESH:D056128', 'Disease') :: ['abdominal obesity']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['MS', 'metabolic syndrome']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['Diastolic dysfunction', 'diastolic dysfunction']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

answer: @entity101 :: (MESH:D006973,Disease) :: ['Hypertension']


abstract: OBJECTIVES: To investigate if typing speed is proportional to the severity of @entity158 with @entity3140 ( @entity3140 ). DESIGN: Standardized functional typing test with @entity1 scoring @entity158 before and after typing; calculation of typing speed. @entity1 : Fifty-nine @entity1 and six controls. SETTING: Tertiary hospital centre for hand and upper @entity158 . MAIN OUTCOME MEASURES: Pain (VAS 0-10) and calculation of typing speed as words per minute. RESULTS: THREE SUBGROUPS OF @entity1 WERE FOUND BASED ON THEIR TYPING SPEED: fast, slow and intermediate. Two-tailed student T-test with P level at 0.05 was used for evaluation. The typing speeds were significantly different between all three @entity1 groups (P < 0.05). The typing speed was significantly faster in the fastest @entity1 group than in the control group (P = 0.04) and the slow and middle groups (P = < 0.0001). The @entity158 before typing was highest in the 'slow' group, in both hands but this difference was not statistically significant. CONCLUSION: Typing speed is not proportional to the severity of @entity158 with @entity3140 . @entity1 with statistically significant slower or faster typing speeds do not have statistically different levels of @entity158 .

title: Is typing speed proportional to the severity of @entity158 with XXXX .

entities_list: @entity3140 :: ('MESH:D038062', 'Disease') :: ['work-related upper limb disorder', 'WRULD']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'patient', 'PATIENTS', 'PARTICIPANTS']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'limb pain', 'pain in keyboard workers']

answer: @entity3140 :: (MESH:D038062,Disease) :: ['work-related upper limb disorder']


abstract: @entity130 affects the success of @entity726 filtering surgery. Antimetabolites and antifibrotic agents are used in the modulation of surgical @entity130 . This study is performed to evaluate the effects of amniotic membrane and @entity2390 on wound healing. Thirty pigmented @entity95 were divided into three groups each including 10 animals. Trabeculectomy and topical postoperative prednisolone @entity10457 four times daily for 7 days were applied to one eye of all the @entity95 . After trabeculectomy, octreotide 10 microg three times daily applied topically to the octreotide group for 14 days and amniotic membrane transplantation was performed by suturing amniotic membrane between scleral flap and sclera to the amniotic membrane group. The operated eyes of the @entity95 were enucleated on the 14th day of the operation and histopathological specimens were obtained from the @entity4530 sites and they were evaluated by light microscope. Fibroblast and macrophage number per cm2 were counted and the average values were calculated. Compared with the control group, the fibroblasts and macrophages significantly decreased in the other two groups (p < 0.0001, p < 0.0001, respectively). The mean number of fibroblasts was lower than those of the control and amniotic membrane groups (p < 0.0001, p < 0.0001, respectively). Similarly the mean macrophage number was significantly lower in the @entity2390 group versus the control and amniotic membrane groups (p < 0.0001, p < 0.01, respectively). @entity2390 administration and amniotic membrane transplantation might be alternative treatments in modulating the wound healing after trabeculectomy.

title: Effects of @entity2390 and amniotic membrane on wound healing in experimental XXXX surgery.

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide', 'Octreotide', 'octreotide acetate']

entities_list: @entity10457 :: ('MESH:C018279', 'Chemical') :: ['sodium phosphate']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['Wound healing', 'trauma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: BACKGROUND: @entity23429 ( @entity23429 ) induces protein glycation and crosslinking, but results in lower solubility and digestibility due to excessive crosslinking. Deamidation of soy protein isolate ( @entity3507 ) by @entity5828 converts @entity3264 residues, and provides less opportunity for the two reactions. Two deamidated @entity3507 products (DSPI1 and DSPI2) were thus @entity4823 -glycated and crosslinked, to clarify the effects of pre-deamidation on the two reactions and properties of the products. RESULTS: DSPI1 and DSPI2 had respective degrees of deamidation of 12.2% and 27.4%. They and @entity3507 were used to generate three glycated and crosslinked products (GC-DSPI1, GC-DSPI2 and GC- @entity3507 ) containing @entity4823 of 12.0, 4.4, and 19.7 g kg(-1) protein, respectively, which were reflected in their infrared spectra at two regions. They three (especially GC- @entity3507 ) had higher water-binding than @entity3507 (8.2-12.6 versus 6.2 g g(-1) protein). GC-DSPI1 and GC-DSPI2 showed better enzymatic digestion than GC- @entity3507 . Thermogravimetric and circular dichroism analyses verified that GC-DSPI1 and GC-DSPI2 had maximum degradation rates at temperatures 12-14   C lower than GC- @entity3507 , and possessed more open secondary structure. CONCLUSION: @entity3507 deamidation decreases forthcoming glycation and crosslinking, and give the products higher digestibility, less increased hydration, lower thermal stability, and more open secondary structure. Pre-deamidation is applicable to control the properties of GC-proteins.

title: Pre-deamidation of soy protein isolate exerts impacts on XXXX -induced @entity4823 glycation and crosslinking as well as properties of the products.

entities_list: @entity23429 :: ('7051', 'Gene') :: ['Transglutaminase', 'TGase']

entities_list: @entity4823 :: ('MESH:D005944', 'Chemical') :: ['glucosamine']

answer: @entity23429 :: (7051,Gene) :: ['transglutaminase']


abstract: UNASSIGNED: Pharmaceutical intervention often requires therapeutics and/or their carriers to enter cells via endocytosis. Therefore, endocytic aberrancies resulting from disease represent a key, yet often overlooked, parameter in designing therapeutic strategies. In the case of @entity2315 ( @entity2315 ), characterized by lysosomal accumulation of undegraded substances, common clinical interventions rely on endocytosis of recombinant enzymes. However, the lysosomal defect in these diseases can affect endocytosis, as we recently demonstrated for clathrin-mediated uptake in @entity1 fibroblasts with type A @entity8706 ( @entity8706 ), a disorder characterized by acid sphingomylinase (ASM) deficiency and subsequent sphingomyelin storage. Using similar cells, we have examined if this is also the case for clathrin-independent pathways, including caveolae-mediated endocytosis and macropinocytosis. We observed impaired @entity5689 enrichment at ligand-binding sites in @entity8706 vs. wild type fibroblasts, corresponding with altered uptake of ligands and fluid-phase markers by both pathways. Similarly, aberrant lysosomal storage of sphingomyelin induced by pharmacological means also diminished uptake. Partial degradation of the lysosomal storage by untargeted recombinant ASM lead to partial uptake enhancement, while both parameters were restored to wild type levels by ASM delivery using model polymer nanocarriers specifically targeted to @entity2071 (anti-ICAM NCs). Carriers also restored @entity5689 enrichment at ligand-binding sites and uptake through the caveolar and macropinocytic routes. These results demonstrate a link between lysosomal storage in @entity8706 and alterations in clathrin-independent endocytosis, which could apply to other @entity2315 . Hence, this study shall guide the design of therapeutic approaches using viable endocytic pathways.

title: Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by XXXX -Targeted Enzyme Delivery.

entities_list: @entity2315 :: ('MESH:D016464', 'Disease') :: ['LSDs', 'lysosomal storage diseases']

entities_list: @entity8706 :: ('MESH:D009542', 'Disease') :: ['Niemann-Pick disease', 'NPD']

entities_list: @entity2071 :: ('3383', 'Gene') :: ['intercellular adhesion molecule-1']

answer: @entity2071 :: (3383,Gene) :: ['ICAM-1']


abstract: Previously published studies on the effect of short-term endurance training on neuromuscular function of the @entity1795 have shown that the @entity8108 -reflex elicited at rest and during @entity425 was increased following the training regime. However, these studies did not test @entity8108 -reflex modulation during isometric maximum voluntary contraction (iMVC) and did not incorporate a control group in their study design to compare the results of the endurance training group to individuals without the endurance training stimulus. Therefore, this randomized controlled study was directed to investigate the neuromuscular function of the @entity1795 at rest and during iMVC before and after 8 weeks of cycling endurance training. Twenty-two young adults were randomly assigned to an intervention group and a control group. During neuromuscular testing, rate of torque development, isometric maximum voluntary torque and muscle activation were measured. Triceps surae muscle activation and tibialis anterior muscle co-activation were assessed by normalized root mean square of the EMG signal during the initial phase of contraction (0-100, 100-200 ms) and iMVC of the @entity1795 . Furthermore, evoked spinal reflex responses of the soleus muscle ( @entity8108 -reflex evoked at rest and during iMVC, V-wave), peak twitch torques induced by electrical stimulation of the posterior tibial nerve at rest and fatigue resistance were evaluated. The results indicate that cycling endurance training did not lead to a significant change in any variable of interest. Data of the present study conflict with the outcome of previously published studies that have found an increase in @entity8108 -reflex excitability after endurance training. However, these studies had not included a control group in their study design as was the case here. It is concluded that short-term cycling endurance training does not necessarily enhance @entity8108 -reflex responses and fatigue resistance.

title: Neuromuscular function and fatigue resistance of the XXXX following short-term cycling endurance training.

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weak voluntary contractions']

entities_list: @entity1795 :: ('MESH:D052582', 'Disease') :: ['plantar flexors']

answer: @entity1795 :: (MESH:D052582,Disease) :: ['plantar flexors']


abstract: OBJECTIVES: @entity3361 is implicated in the pathogenesis of @entity1187 including @entity583 ( @entity583 ). Stent implantation in the primary percutaneous coronary intervention is the first choice of treatment for @entity1 with @entity583 . However, the relationship between @entity3361 and stent implantation after @entity583 and its clinical implications remain unknown. We examined the incidence and clinical implications of provoked @entity3361 after stent implantation in @entity1 with @entity583 . METHODS: Fifty-seven @entity1 (43 @entity1 and 14 @entity1 with a mean age of 65.1  12.5 years) with ST elevation @entity583 who had undergone a stent implantation were the @entity1 of this study. They underwent a provocation test for @entity3361 by intracoronary injection of @entity934 2-5 weeks after the attack. The @entity1 with provoked @entity2473 were given @entity460 channel blockers, and all the @entity1 of the study were followed up for an average of 35.0  26.9 months. RESULTS: @entity3361 was induced in 40 (70.2%) and multivessel @entity2473 in 17 (29.8%) of the 57 @entity1 . Spasms occurred in 31 (55.4%) of the @entity1188 ( @entity1188 ) and 33 (30.6%) of the non- @entity1188 . There was no significant difference (  =1.01, P=0.314) in the major @entity299 between the @entity2473 group and nonspasm group during the follow-up. CONCLUSION: @entity3361 was provoked with a high frequency in both the @entity1188 and non- @entity1188 after stent implantation in @entity1 with @entity583 . @entity460 channel blockers may be useful to improve the prognosis in @entity1 with @entity583 after stent implantation by suppressing @entity3361 .

title: High incidence of provoked @entity3361 in the presence of a stent after XXXX : therapeutic and prognostic implications.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'men']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes']

entities_list: @entity3361 :: ('MESH:D003329', 'Disease') :: ['Coronary spasm', 'coronary spasm']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['IRAs', 'infarct-related arteries']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: BACKGROUND: @entity284 (ME) is commonly used in @entity158 ( @entity158 ) @entity1 with @entity158 or intolerable opioid adverse effects (AEs). A unique ME AE is its corrected QT (QTc) interval prolongation risk, but most evidence exists in @entity284 maintenance therapy @entity1 . OBJECTIVE: Our goal was to identify QTc interval prolongation risk factors in @entity158 @entity1 receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool. DESIGN: We performed a case-control study of adult inpatients receiving ME for @entity158 management. Settings/Subjects: Adult inpatients receiving ME with a QTc >470   msec (males) and >480   msec (females) were matched 1:2 according to age, history of @entity1162 , and gender with ME @entity1 who did not have a @entity1162 . @entity1162 risk factors were collected for both groups. Covariates were analyzed using conditional logistic regression. Classification and regression tree analysis was used to identify the ME dose associated with @entity1162 . RESULTS: Predictors of @entity1162 included @entity712 ( @entity712 ) (OR: 11.9; 95% CI: 3.7-38.2; p   <   0.00), @entity10189 ( @entity10189 ) (odds ratio [OR]: 8.3; 95% confidence interval [95% CI]: 2.4-28.9; p   <   0.00), @entity1371 (OR: 6.5; 95% CI: 1.5-28.2; p   <   0.01), @entity66 (OR: 4.7; 95% CI: 1.6-13.9; p   <   0.00), taking medications with a known @entity1166 ( @entity1166 ) risk (OR: 4.4; 95% CI: 1.8-10.7; p   <   0.01), @entity5 (OR: 3.3; 95% CI: 1.2-9.3; p   <   0.03), @entity3747 (OR: 2.1; 95% CI: 0.9-4.8; p   <   0.07), and ME doses >45   mg per day (OR: 1.9; 95% CI: 0.8-4.8; p   <   0.16). Mild @entity409 was protective against @entity1162 (OR: 0.05; 95% CI: 0.0-0.46; p   <   0.01). CONCLUSIONS: Predictors of @entity1162 in our multivariate conditional logistic regression model included @entity712 , @entity10189 , @entity1371 , @entity74 , use of medications with a known @entity1166 risk, @entity5 , @entity3747 , and ME doses >45   mg per day.

title: @entity284 and Corrected QT Prolongation in XXXX and Palliative Care @entity1 : A Case-Control Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3747 :: ('MESH:D006996', 'Disease') :: ['hypocalcemia']

entities_list: @entity10189 :: ('MESH:D010437', 'Disease') :: ['peptic ulcer disease', 'PUD']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'CHF']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['rheumatologic diseases']

entities_list: @entity1166 :: ('MESH:D016171', 'Disease') :: ['TdP', 'torsades de pointes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['rheumatologic disorders']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['PPC', 'pain and palliative care', 'pain', 'refractory pain']

entities_list: @entity284 :: ('MESH:D008691', 'Chemical') :: ['methadone', 'Methadone']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['QTc prolongation', 'prolonged QTc interval']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia']

answer: @entity158 :: (MESH:D010146,Disease) :: ['Pain']


abstract: Repeated @entity935 agonist administration to @entity35 with unilateral @entity2955 lesions of the nigrostriatal pathway potentiates behavioral and neuronal activation in response to subsequent @entity935 agonist treatment. This response sensitization has been termed "priming" or "reverse-tolerance". Our prior work has shown that three pretreatment injections of the mixed D1/D2 agonist @entity3826 (0.5 mg/kg) into @entity2955 -lesioned @entity35 permits a previously inactive dose of the D2 agonist @entity11640 (0.25 mg/kg) to induce robust @entity717 and striatal @entity5019 expression in striatoentopeduncular "direct" pathway neurons. These striatal neurons typically express D1 but not D2 receptors. Because @entity3826 acts as an agonist at both D1 and D2 receptors, the present study sought to determine whether D1, D2, or concomitant D1/D2 receptor stimulation was required to prime D2-mediated @entity717 and striatal @entity5019 expression. Twenty-one days following unilateral stereotaxic injection of @entity2955 into the medial forebrain bundle, @entity35 received three pretreatment injections, at three- to six-day intervals, with either: the mixed D1/D2 agonist @entity3826 , the D1 agonist @entity2344 , the D2 agonist @entity11640 , or a combination of @entity2344 + @entity11640 . Ten days following the third pretreatment injection, @entity2955 -lesioned @entity35 were challenged with the D2 agonist @entity11640 (0.25 mg/kg). Pretreatment with @entity2344 (10 mg/kg), @entity11640 (1 mg/kg) or @entity2344 (1 mg/kg) + @entity11640 (0.25 mg/kg) permitted an otherwise inactive dose of @entity11640 (0.25 mg/kg) to induce robust @entity717 which was similar in magnitude to that observed following @entity3826 priming. However, only pretreatment with @entity2344 (10 mg/kg) or @entity2344 (1 mg/kg) + @entity11640 (0.25 mg/kg) permitted the same dose of @entity11640 (0.25 mg/kg) to induce striatal @entity5019 expression. These results demonstrate that while prior stimulation of D1, D2 or D1/D2 receptors can effectively prime D2-mediated @entity717 , prior stimulation of D1 receptors is required to prime D2-mediated striatal @entity5019 expression. This study demonstrates that priming of @entity2955 -lesioned @entity35 with a D1 agonist permits a subsequent challenge with a D2 agonist to produce robust rotational behavior that is accompanied by induction of immediate-early gene expression in neurons that comprise the "direct" striatal output pathway. These responses are equivalent to the changes observed in @entity3826 -primed @entity2955 -lesioned @entity35 challenged with D2 agonist. In contrast, D2 agonist priming was not associated with D2-mediated induction of striatal immediate-early gene expression even though priming of D2-mediated rotational behavior was not different from that observed following priming with @entity3826 or D1 agonist. Therefore, while priming-induced alterations in D2-mediated immediate early gene expression in the "direct" striatal output pathway may contribute to the enhanced motor behavior observed, such changes in striatal gene expression do not appear to be required for this potentiated motor response in @entity935 -depleted @entity35 .

title: Prior D1 XXXX receptor stimulation is required to prime D2-mediated striatal @entity5019 expression in @entity2955 -lesioned @entity35 .

entities_list: @entity11640 :: ('MESH:D019257', 'Chemical') :: ['quinpirole']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity3826 :: ('MESH:D001058', 'Chemical') :: ['apomorphine']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['contralateral rotation']

entities_list: @entity2955 :: ('MESH:D016627', 'Chemical') :: ['6-hydroxydopamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: The @entity1 is a 12-year-old @entity1 with a history of @entity4207 , @entity851 , and strabismus. Weight, height and head circumference were below the 3rd percentile. A caf  -au-lait spot, 1x1 cm a diameter, on the back region and @entity1408 were diagnosed. He had facial asymmetry, a broad nose, @entity18026 , a @entity50 , deviation of the nasal septum, and bilateral small maxillary bones. The left orbital fossa was also mildly rudimentary. On eye examination the movements of the left globe to the upward and lateral side were limited and internal strabismus was noted at this side. Visual acuity was 1/10, bilaterally. Bilateral @entity3193 , @entity726 , @entity346 were diagnosed. Fundoscopic examination revealed bilateral optic atrophy and macular and paramacular granulation tissues on the left side. Intelligence quotient was 46. Electroencephalography revealed bilateral frontal slow-wave activity. Visual evoked potential revealed prolonged @entity7286 wave latencies bilaterally. Magnetic resonance imaging of the brain demonstrated @entity6789 dysgenesis, bilateral subcortical @entity75 in the posterior horn of the left ventricle. Chromosomal analysis revealed a normal male karyotype, 46, XY. Although several cases of @entity3664 in association with @entity1032 , @entity2122 , cerebral, and @entity735 have been described the combination of abnormalities diagnosed in our case has not previously been reported. We hypothesize that the combination of @entity4289 , @entity6789 dysgenesis, @entity2122 , severe @entity735 , and growth- @entity1032 may be a new syndrome.

title: A Turkish case of @entity4289 associated with @entity6789 dysgenesis, @entity2122 , severe XXXX , and growth- @entity1032 .

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['rudimentary frontal sinus']

entities_list: @entity2122 :: ('MESH:D019465', 'Disease') :: ['craniofacial dysmorphism']

entities_list: @entity4289 :: ('MESH:D054221', 'Disease') :: ['subcortical/subependymal heterotopia']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['heterotopia in the frontal lobes and subependymal heterotopia']

entities_list: @entity3664 :: ('MESH:C548481', 'Disease') :: ['heterotopia']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['eye abnormalities']

entities_list: @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroid coloboma']

entities_list: @entity4207 :: ('MESH:D007859', 'Disease') :: ['learning disability']

entities_list: @entity6789 :: ('MESH:D061085', 'Disease') :: ['corpus callosum']

entities_list: @entity18026 :: ('MESH:C563111', 'Disease') :: ['sparse eyebrows and eyelashes']

entities_list: @entity346 :: ('MESH:D009759', 'Disease') :: ['vertical and horizontal nystagmus']

entities_list: @entity1408 :: ('MESH:D005660', 'Disease') :: ['pectus excavatum deformity']

answer: @entity735 :: (MESH:D005124,Disease) :: ['eye abnormalities']


abstract: Oxidative radicals, which are produced during ionizing irradiation of DNA in water, damage the DNA and may result in mutations, which are in general randomly distributed. Alternatively, the addition of @entity9546 ions, like @entity68 or @entity920 , to DNA in combination with @entity274 and a reducing agent also results in the production of oxidative radicals. Due to binding of the @entity9546 ions to DNA, the production of these radicals is very local, and results in a mutational spectrum in which the mutations are not randomly distributed. If @entity9546 ions are complexed to the DNA during irradiation, and react with radiation-induced species such as @entity273 , site-specific formation of. @entity2145 radicals on these sites may occur, leading to the formation of mutational hot spots. This study examines the influence of the presence of traces of @entity68 or @entity920 ions during gamma-irradiation of plasmid DNA in water, on the possible formation of mutational hot spots in the @entity11524 gene. Comparison of the mutational spectra, after irradiation in the presence or in the absence of @entity9546 ions, shows that there are indeed relatively more positions in the @entity11524 gene where more than one mutation occurs, suggesting formation of mutational hot spots in the presence of @entity9546 ions. However, the appearance of these hot spots is rather weak. Although in all three mutational spectra G:C to A:T mutations are predominant, there are also some differences between the types of mutations in these spectra. These differences in mutational spectra might reflect the different preferences of @entity68 and @entity920 ions to bind specific sites in the DNA. Indeed, there appears to be a high association of mutations at CC or GG sites in the mutational spectrum in the presence of @entity920 ions, confirming the observation that @entity920 binds preferably at two adjacent guanines in the DNA. It can be concluded from this study that the presence of small amounts of @entity9546 ions during gamma-irradiation influences the types and distribution of gamma-radiation-induced mutations, although no major mutational hot spots can be observed.

title: The presence of traces of @entity68 and XXXX ions during gamma-irradiation does not result in clear mutational hot spots in the @entity11524 gene.

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity9546 :: ('CHEBI:27081', 'Chemical') :: ['transition metal']

answer: @entity920 :: (MESH:D003300,Chemical) :: ['copper']


abstract: We previously reported that @entity15630 deficiency prevents collagen deposition in the airways of ovalbumin (OVA)-challenged @entity19 . In this study, we explored the therapeutic utility of blocking @entity15630 in preventing airway remodeling, using a specific @entity15630 inhibitor, @entity42421 . C57BL/6J @entity19 were immunized with intraperitoneal injections of OVA on Days 0, 3, and 6. Starting on Day 11, @entity19 were challenged with @entity1391 -buffered saline or OVA by nebulization three times per week for 4 weeks. @entity42421 was mixed with chow and administered orally from 1 day before the @entity1391 -buffered saline or OVA challenge. Lung tissues were harvested after challenge and characterized histologically for infiltrating inflammatory cells, mucus-secreting goblet cells, and collagen deposition. Airway hyperresponsiveness was measured using whole-body plethysmography. @entity42421 treatment significantly decreased levels of @entity15630 activity in bronchoalveolar lavage fluids, which indicates successful blockage of @entity15630 activity in the airways. The number of infiltrated inflammatory cells was reduced by @entity42421 treatment in the lungs of the OVA-challenged @entity19 . Furthermore, oral administration of @entity42421 significantly attenuated the degree of @entity1373 and collagen deposition in the airways of the OVA-challenged @entity19 , and @entity2710 -induced airway hyperresponsiveness was effectively reduced by @entity42421 in these animals. This study supports our previous findings that @entity15630 promotes airway remodeling in a @entity19 model of @entity102 , and suggests that @entity15630 may be a novel target of treatment of airway remodeling in @entity565 .

title: A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a XXXX model of @entity102 .

entities_list: @entity42421 :: ('MESH:C488103', 'Chemical') :: ['tiplaxtinin', 'Tiplaxtinin']

entities_list: @entity15630 :: ('18787(Tax:10090)', 'Gene') :: ['plasminogen activator inhibitor (PAI)-1', 'PAI-1']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['goblet cell hyperplasia']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic asthma']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine']

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: PURPOSE: In Canada there is growing concern that waiting time for @entity5 surgery has been increasing. We used population based data to estimate the average @entity1726 for RC in Quebec and assess whether delayed surgery has a negative impact on long-term survival. MATERIALS AND METHODS: We used the provincial billing database of the maladie du Quebec to identify all @entity1 with @entity150 18 years or older who underwent RAMQ from 1990 to 2002. @entity1726 was calculated as the time elapsed between the most recent transurethral resection and the date of RC. @entity1 were categorized according to @entity1726 tertiles into 3 groups, namely 1) 20 or less, 2) 21 to 47 and (C) 48 days or greater. Cox proportional hazards models were used to assess the effect of @entity1726 on overall survival, while adjusting for @entity1 and provider factors. RESULTS: During the study period 1,592 radical cystectomies were performed. Overall median @entity1726 was 33 days (95% CI 30 to 35). Median @entity1726 increased from 23 days in 1990 to 50 in 2002. After adjusting for calendar year, and @entity1 and provider variables there were no significant differences in survival among the 3 delay categories. However, @entity1 subject to greater than 12 weeks of delay were at 20% greater risk for dying (95% CI 1.0 to 1.5, p = 0.051). CONCLUSIONS: In line with previous reports @entity1726 greater than 12 weeks seems to be associated with a worse long-term prognosis.

title: Effect of preoperative delay on survival in XXXX with @entity150 undergoing cystectomy in Quebec: a population based study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: We present recurrent 15q11.2 ( @entity66144 ) microdeletion encompassing @entity66145 , @entity31568 , @entity35862 , and @entity66146 in a family with phenotypic variability in developmental, speech, and @entity1957 . CASE REPORT: A 32-year-old @entity1 underwent amniocentesis at 17 weeks of gestation because of an abnormal maternal serum screening result of Down syndrome risk of 1/226. Her husband was 31 years old. She and her husband were phenotypically normal, and there was no family history of @entity146 and @entity600 . Amniocentesis revealed a karyotype of 46,XX. Prenatal ultrasound findings were unremarkable. A 2492-g female baby was delivered at 37 weeks of gestation uneventfully. During the subsequent pregnancy, the same @entity1 at the age of 35 years underwent amniocentesis at 18 weeks of gestation because of advanced maternal age, which revealed a karyotype of 46,XY. Prenatal ultrasound findings were unremarkable. A 2780-g male baby was delivered at 37 weeks of gestation uneventfully. About 3 years after the birth of this @entity1 , array comparative genomic hybridization of the family revealed 15q11.2 microdeletion encompassing @entity66145 , @entity31568 , @entity35862 , and @entity66146 in the two siblings, who displayed developmental, speech, and @entity1957 , and in their phenotypically normal father. CONCLUSION: Recurrent phenotypic abnormality in the family with normal karyotype at amniocentesis should include a differential diagnosis of familial pathogenic copy-number variations.

title: Familial transmission of recurrent 15q11.2 ( @entity66144 ) microdeletion encompassing XXXX , @entity31568 , @entity35862 , and @entity66146 associated with phenotypic variability in developmental, speech, and @entity1957 .

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['congenital malformations']

entities_list: @entity1957 :: ('MESH:D019957', 'Disease') :: ['motor delay']

answer: @entity66145 :: (123606,Gene) :: ['NIPA1']


abstract: A @entity1 with an 11 year history of @entity7965 presented with severe @entity490 . On admission, the hematocrit value was 30 per cent and unchanged from repeated measurements during the previous three years. Abdominal angiography identified extensive @entity1150 . After initial improvement on heparin therapy, the @entity1 experienced additional abdominal crises. A ruptured and multifragmented spleen was removed at the time of exploratory laparotomy. Postoperatively, after a several days' interval of improvement, the @entity1 experienced additional @entity715 episodes of the abdomen, upper extremities and cerebral cortex. The latter was associated with disabling @entity2895 . With continuous intravenous heparin plus @entity134 therapy, the @entity1 's condition improved progressively. Despite the numerous @entity715 episodes during the prolonged hospital course, no hemolytic episodes were observed. This is the first report of documented @entity9440 in a @entity1 with @entity7965 .

title: Venous thrombosis and @entity9440 in XXXX .

entities_list: @entity2895 :: ('MESH:D015840', 'Disease') :: ['nerve paralysis']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['thromboses of the splenic and portal venous systems']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity7965 :: ('MESH:D006457', 'Disease') :: ['paroxysmal nocturnal hemoglobinuria']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

entities_list: @entity9440 :: ('MESH:D013161', 'Disease') :: ['splenic rupture']

answer: @entity7965 :: (MESH:D006457,Disease) :: ['paroxysmal nocturnal hemoglobinuria']


abstract: UNASSIGNED: Lesion mimic mutants commonly display spontaneous cell death in pre-senescent green leaves under normal conditions, without pathogen attack. Despite molecular and phenotypic characterization of several lesion mimic mutants, the mechanisms of the spontaneous formation of cell death lesions remain largely unknown. Here, the @entity579 lesion mimic mutant spotted leaf3 (spl3) was examined. When grown under a light/dark cycle, the spl3 mutant appeared similar to wild-type at early developmental stages, but lesions gradually appeared in the mature leaves close to heading stage. By contrast, in spl3 mutants grown under continuous light, severe cell death lesions formed in developing leaves, even at the seedling stage. Histochemical analysis showed that @entity273 accumulated in the mutant, likely causing the cell death phenotype. By map-based cloning and complementation, it was shown that a 1-bp deletion in the first exon of @entity579 Mitogen-Activated Protein Kinase Kinase Kinase1 (OsMAPKKK1)/OsEDR1/OsACDR1 causes the spl3 mutant phenotype. The spl3 mutant was found to be insensitive to @entity2271 ( @entity2272 ), showing normal root growth in @entity2272 -containing media and delayed leaf yellowing during dark-induced and natural senescence. Expression of @entity2272 signalling-associated genes was also less responsive to @entity2272 treatment in the mutant. Furthermore, the spl3 mutant had lower transcript levels and activities of catalases, which scavenge @entity273 , probably due to impairment of @entity2272 -responsive signalling. Finally, a possible molecular mechanism of lesion formation in the mature leaves of spl3 mutant is discussed.

title: Mutation of SPOTTED LEAF3 (SPL3) impairs XXXX -responsive signalling and delays leaf senescence in @entity579 .

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity2271 :: ('MESH:D000040', 'Chemical') :: ['abscisic acid']

entities_list: @entity579 :: ('4530', 'Species') :: ['Oryza sativa', 'rice']

answer: @entity2271 :: (MESH:D000040,Chemical) :: ['abscisic acid']


abstract: AIM: The prognosis has markedly improved during the last years after mild and moderate @entity542 . After severe @entity542 , this evolution could not be observed so far. This requires a better understanding of pathophysiological interaction, especially in the subacute and late phase of @entity130 . METHODS: Review article. DISCUSSION: Causes for the development of secondary @entity75 are the intracranial space demand after @entity130 and @entity4 formation which max result in @entity63 , as well as inflammatory processes. Both isolated severe @entity542 and polytrauma with or without @entity75 may result in a @entity1850 due to the synthesis of cytokines and other inflammatory mediators which may cause a single or @entity881 . The @entity2495 after severe @entity542 is often regarded as an interaction between the central nervous system and the whole organism by the activation of the @entity8799 . Moreover, coagulation, metabolism and @entity174 healing are influenced by the onset of SIRS as well. CONCLUSION: Our knowledge about the bidirectional inflammatory interaction between brain and whole organism is still limited. It is generally accepted that extracranial complications are highly influential in determining the outcome from severe @entity542 .

title: [Craniocerebral XXXX --new pathophysiological and therapeutic viewpoints].

entities_list: @entity8799 :: ('MESH:D018358', 'Disease') :: ['neuroendocrine axis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head trauma', 'head injuries', 'head injury']

entities_list: @entity2495 :: ('MESH:C565498', 'Disease') :: ['hypermetabolism']

entities_list: @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome']

entities_list: @entity881 :: ('MESH:D009102', 'Disease') :: ['multiple organ failure']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['traumatic injury', 'trauma']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']


abstract: PURPOSE: We report a case in which a @entity1 sustained a dural tear during spinal surgery under general anesthesia complicated by a severe and persistent unilateral @entity1274 . CLINICAL FINDINGS: A 51-yr-old @entity1 with no previous otological history underwent a @entity5663 surgery in the prone position under general anesthesia. A small dural tear was discovered intra-operatively and was repaired by sutures. Surgery lasted for eight hours with over 3 L of @entity190 . Recovery from anesthesia was otherwise uneventful. A unilateral right-sided @entity1274 was discovered shortly after completion of surgery. This was associated with mild @entity392 but no vertigo. There was no aural fullness, @entity158 , @entity10 or postural element to his symptoms. Despite extensive investigations, treatment and follow-up by an otorhinolaryngologist, his symptoms failed to improve 18 months following surgery. DISCUSSION: The possible etiologies, preventive strategies, prognosis and management plan of this rare complication are discussed.

title: Postoperative sudden @entity1274 after XXXX : a case report.

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5663 :: ('MESH:D003665', 'Disease') :: ['posterior lumbar decompression']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['tinnitus']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity5663 :: (MESH:D003665,Disease) :: ['posterior lumbar decompression']


abstract: UNASSIGNED: BackgroundSince there is evidence that mental health aspects (such as @entity308 ) may inhibit an optimal rehabilitation outcome, there is growing interest in the psychosocial aspects of @entity1018 as part of rehabilitation. The purpose of this study is to provide more insight into the construct validity and (longitudinal) interpretation of goals related to  Coping with @entity1032 aspects   which are part of the recently developed  Dutch ICF Activity Inventory (D-AI). Moreover, the data allowed to provide some insight in the outcome in this domain in relation to rehabilitation programs followed in @entity826 Rehabilitation Centers at baseline and follow-up.MethodsIn a cohort of 241 visually impaired @entity1 , the D-AI was assessed at baseline (enrollment), 4 and 12  months, The importance and difficulty of the D-AI goals  Handle feelings  ,  Acceptance  , and  Feeling fit   and difficulty scores of underlying tasks were further analyzed, together with similar or related standardized questionnaires. At baseline, Spearman correlations were determined between D-AI goals and task and additional questionnaires to investigate the construct validity. Corrected and uncorrected linear mixed models were used to determine longitudinal rehabilitation outcomes in relation to rehabilitation programs followed.ResultsBaseline correlations indicated that the difficulty of tasks and the umbrella goal  Acceptance   were not similar. Longitudinal analyses provided insight in some subtle differences in concepts measured at the goal and task level of the D-AI, as well as similar validated questionnaires. After correcting for confounding variables, none of the underlying task difficulty scales changed over time. For goal difficulty scores only  Acceptance   was reported to be significantly less difficult at 4 and 12  months follow-up. Importance scores of goals were stable from baseline to follow-up.ConclusionWith respect to the constructs measured, results support the formulation of the new goal question  Emotional life   which replaces the goals  Handle feelings   and  Acceptance  . Results indicate that MRCs should pay more attention to problems related to mental health. They have started to use the D-AI as it seems a promising tool to investigate and evaluate rehabilitation needs (including those related to mental health) over time and to clearly define rehabilitation goals from the very start.

title: Longitudinal observation, evaluation and interpretation of coping with XXXX in low vision rehabilitation using the Dutch ICF Activity Inventory.

entities_list: @entity1018 :: ('MESH:D054062', 'Disease') :: ['vision loss']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental (emotional) health']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity826 :: ('MESH:D054078', 'Disease') :: ['Dutch Multidisciplinary']

answer: @entity1032 :: (MESH:D008607,Disease) :: ['mental (emotional) health']